Some cases of hypermobile Ehlers-Danlos syndrome may be rooted in mast cell activation syndrome
- PMID: 34719842
- DOI: 10.1002/ajmg.c.31944
Some cases of hypermobile Ehlers-Danlos syndrome may be rooted in mast cell activation syndrome
Abstract
Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common type of EDS, yet has remained steadfastly inscrutable vis-à-vis efforts to identify its cellular, molecular, and pathophysiologic roots. Once thought to principally affect just connective tissues, hEDS is now appreciated to be a multisystem disease of great heterogeneity with many symptoms and findings difficult to attribute solely to disordered connective tissue development. In the last decade, there has been growth in the appreciation of the existence of a wide range of disorders of chronic inappropriate mast cell (MC) activation (a large heterogeneous pool of MC activation syndromes [MCAS]) distinguishable from other MC disorders such as rare neoplastic mastocytosis. Via chronic aberrant release of the MC's vast repertoire of potent mediators, MCAS can drive extraordinary arrays of pathologies, most commonly of inflammatory, allergic, and dystrophic natures. Although hEDS is seen in only a minority of MCAS cases, limited studies have identified an association between hEDS and MCAS, fueling speculation that certain variants of MCAS may drive hEDS. No laboratory studies probing cellular or molecular linkages between hEDS and MCAS have been conducted yet, and research efforts to identify the genetic roots of hEDS should also consider those of MCAS.
Keywords: Ehlers-Danlos syndrome; hypermobility; mast cell activation disease; mast cell activation syndrome; medical hypothesis.
© 2021 Wiley Periodicals LLC.
References
REFERENCES
-
- Afrin, L. B. (2014). The presentation, diagnosis, and treatment of mast cell activation syndrome. Current Allergy & Clinical Immunology, 27(3), 146-160.
-
- Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., … Molderings, G. J. (2020). Diagnosis of mast cell activation syndrome: A global “consensus-2”. Diagnosis (Berlin), 8, 137-152. https://doi.org/10.1515/dx-2020-0005
-
- Afrin, L. B., Cichocki, F., Hoeschen, A., Beckman, K. B., Gupta, K., Nguyen, J., … Mills, L. J. (2016). Mast cell regulatory gene variants are common in mast cell activation syndrome. Blood, 128(22), 4878. https://doi.org/10.1182/blood.V128.22.4878.4878
-
- Afrin, L. B., Self, S., Menk, J., & Lazarchick, J. (2017). Characterization of mast cell activation syndrome. The American Journal of the Medical Sciences, 353(3), 207-215. https://doi.org/10.1016/j.amjms.2016.12.013
-
- Altmüller, J., Haenisch, B., Kawalia, A., Menzen, M., Nöthen, M. M., Fier, H., & Molderings, G. J. (2017). Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing. Immunogenetics, 69(6), 359-369. https://doi.org/10.1007/s00251-017-0981-y
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
